Ticrynafen

Summary

Ticrynafen (CHEMBL267744) is an approved small-molecule loop diuretic (ATC C03CC02); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03CC02
• Indications: 1 condition
• Chemistry: 331.2 Da · C13H8Cl2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL267744
Name	Ticrynafen
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	38409
ChEBI	CHEBI:9590
ATC	C03CC02
Molecular formula	C13H8Cl2O4S
Molecular weight	331.2
InChIKey	AGHANLSBXUWXTB-UHFFFAOYSA-N

SMILES: C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl

IUPAC name: 2-[2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy]acetic acid

ChEBI definition: An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.

Pharmacological roles (ChEBI): loop diuretic, antihypertensive agent, hepatotoxic agent.

Also known as: Acide tienilique, Acido tienilico, Selacryn, SK&F 62698, SK&F-62698, Ticrynafen, Tienilic acid, Tienilic Acid, SID29215401, ticrynafen, SID29215402, TICRYNAFEN

Patent coverage: 954 distinct patent families (3,149 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,148 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Fructose-bisphosphate aldolase, Aldo-keto reductase family 1 member B1, Cytochrome P450 2C9.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P07943	5.49	IC50	3206	nM	CHEMBL_ACT_7815071
CYP2C9	5.37	Ki	4300	nM	CHEMBL_ACT_6075060

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).